An FDA panel voted 8-6 to recommend BPC-157. Almost nothing changed that day.

2026-09-20

On 23 July 2026, an FDA advisory committee voted on BPC-157.

The tally was 8 in favour, 6 against, one abstention. The question was whether to recommend adding it to the 503A Bulks List.

Coverage read like a verdict. ABC News ran the headline "FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list."

But a committee cannot add anything to that list. Four things sit between that vote and any change in what is legal.

1. The vote binds nobody

Every outlet said so, including the one whose headline did not.

ABC News states in its own text that the vote "is non-binding and still needs sign-off from the FDA." The National Community Pharmacists Association puts it plainly: "PCAC's votes are recommendations and are not binding on the FDA."

An advisory committee advises. That is the whole of its power.

2. FDA's own staff had proposed the opposite

This is the part that goes missing in most coverage.

Ten weeks before the vote, FDA published its own evaluation of BPC-157. It is dated 11 May 2026. It concluded that the statutory criteria came out against, and said so directly: "Accordingly, we propose not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List."

FDA gave four grounds:

Neither form is well characterised, physically or chemically.
Information on safety and immunogenicity risk is lacking.
The evidence is not enough to reach a conclusion on effectiveness.
Approved products already exist for the condition.

So the committee voted against its own agency's staff. That happens, and there is nothing improper about it. But it means this was not FDA agreeing with itself. It was a panel disagreeing with the agency. The agency has not said which view wins.

3. Placement takes rulemaking, not a show of hands

Pharmaceutical Executive notes that getting on the list still requires formal rulemaking. It puts that at eight to twelve months.

Until that finishes, the list is unchanged. As of this writing, BPC-157 is not on it.

4. FDA has published no record of the vote

This one is easy to check, and worth checking.

Go to FDA's page for the meeting. You will find plenty:

Briefing documents for all seven substances
The voting questions
The final agenda and the meeting roster
The presentation slides
A note that archived webcasts are planned

You will not find minutes. You will not find a transcript. You will not find a vote record.

Everything anyone knows about that vote comes from reporters who were watching.

That is not a criticism of the reporters. But it means something. Every tally quoted anywhere, this article included, rests on press accounts. No FDA document confirms them.

What the tallies were

Reported figures, since they are in no official record:

Substance	Reported vote
BPC-157	8-6, one abstention
KPV	8-6, one abstention
TB-500	8-6, one abstention
MOTS-c	7-5, two abstentions
Epitalon	recommended, no tally reported
Semax	recommended, no tally reported
Emideltide	not recommended

Pharmaceutical Executive is the only source found that gives a separate tally for each substance. The NCPA covers the second day. It reports that six of the seven were recommended, with Emideltide the exception.

Two details are worth carrying.

STAT reports that most of the panelists who voted yes have ties to the peptide industry. That observation appears in none of the other coverage found.

And Pharmaceutical Executive quotes a committee member during the proceedings: "I'm voting on something here, but I don't know what that something is."

Why 8-6 is the interesting number

A one-vote swing would have flipped it.

The agency's own scientists had recommended no. On that question, a panel split nearly down the middle is not a clear signal either way.

You can fairly read the vote as a sign that opinion is moving. You cannot read it as a finding about whether BPC-157 works. The committee was not asked that. And nothing in the evidence changed between May and July.

What would actually be news

If you are tracking this, four things would matter:

FDA publishing minutes, a transcript, or a vote record.
FDA responding to the recommendation, either way.
A proposed rule appearing in the Federal Register.
Any new human data at all. FDA's May evaluation found none by any route people actually use.

None of those has happened yet. Until one does, the position is what FDA said in May, and a panel said otherwise in July.

Sources

All articles